KR101921202B1 - Novel triazolylsalicylamide derivatives with aurora kinase inhibiting activity - Google Patents

Abstract

The present invention relates to a novel triazolyl salicylamide derivative having an Aurora kinase inhibitory effect, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same as an active ingredient. The novel triazolyl salicylamide derivative Derivatives are effective for the prevention or treatment of diseases related to Aurora kinase, e.g., various cancers, due to their excellent inhibitory effect on Aurora kinase.

Description

Novel triazolylsalicylamide derivatives with aurora kinase inhibiting activity and novel triazolyl salicylamide derivatives having aurora kinase inhibitory activity [

The present invention relates to a novel triazolyl salicylamide derivative exhibiting an inhibitory effect on aurora kinase, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient.

Aurora kinase is a kinase belonging to the serine / threonine kinase that regulates cell division.

Three human structural isoforms of Aurora kinase (Aurora A, Aurora B, and Aurora C) exhibit distinct functions and different intracellular distribution during cell mitosis and exhibit different functions. Aurora B is located in the central body of the cytoplasm, central spindle, and spindle body, and participates in centrosome separation, chromosome division and cytoplasmic division, while Aurora A is located in the central body and participates in centrosome maturation and dipole spindle formation. Aurora A is a chromosomal passenger protein kinase and regulates the phosphorylation of histone H3 in the 10th serine. Aurora C is located at the apical pole at the end of mitosis and is also considered as a chromosome passenger to complement the function of Aurora B in mitotic cells.

Overexpression of Aurora A and B results in hyperphosphorylation of normal mitotic cycle targets and variant phosphorylation of cytoplasmic targets leading to chromosomal instability, oncogenic transformation, tumor progression, and development of resistance to anti-cancer agents. Thus, over-expression of aurora kinase is often observed in various cancer cells such as large intestine, pancreas, breast, lung, thyroid, and leukemia. A number of recent reports have shown that Aurora Kinase is an attractive anti-cancer drug target. The inhibition of Aurora A induces the abnormal formation of spindle vertebrae and the formation of immature central body, thus forming a monolayer of the unipolar at the mitosis and stopping the mitosis. Inhibition of Aurora B induces mitotic closure resulting in the formation of drainage cells do.

On the other hand, compound VX-680 (formula A) having the following structure is in clinical trials as the first Aurora kinase inhibitor, and a number of aurora-selective low molecular inhibitors have been developed and are currently undergoing preclinical and clinical evaluation . Specific examples of these compounds include compounds SNS-314 (Formula B), MLN-8237 (Formula C), MK-5108 (Formula D), AZD-1152 (Formula E), GSK-1070916 (Formula F) . Aurora A-specific inhibitors, AZD-1152, GSK-107916, and Aurora B (Aurora B) inhibitors were selected for the Aurora subspecies, VX-680 and SNS-314 as pan- Specific inhibitors. Despite these intensive efforts to date, there is no Aurora-selective drug approved by the FDA yet.

(A)

[Chemical Formula B]

≪ RTI ID = 0.0 &

[Chemical Formula D]

(E)

[Chemical Formula F]

In this context, the present inventors have made efforts to develop aurora-selective kinase inhibitors, and as a result, they have developed 1,2,3-triazolyl salicylamide derivatives that exhibit an excellent inhibitory effect on aurora kinase, Respectively.

Accordingly, an object of the present invention is to provide a novel compound which effectively inhibits Aurora kinase.

Still another object of the present invention is to provide a pharmaceutical composition for preventing or treating Aurora kinase-related diseases comprising the above-mentioned compound as an active ingredient.

In one aspect of the present invention, the present invention relates to a triazolyl salicylamide derivative represented by the following formula (1) or a pharmaceutically acceptable salt thereof, which effectively inhibits aurora kinase.

[Chemical Formula 1]

In this formula,

R < ¹ > is hydrogen or hydroxy;

R ² is hydrogen, halogen, C _{1 - 6} alkyl, OC _{1 - 6} alkyl or COOR 'and;

Ar is substituted with a substituent X of from 1 to 4 unsubstituted or substituted with C _6-10 aryl, or X of 1 to 4 unsubstituted or is O, S, and from 1 to 3 heteroatoms selected from the group consisting of N Lt; RTI ID = 0.0 > of: < / RTI >

X is hydrogen, halogen, C _{1 - 6} alkyl, OC _{1 - 6} alkyl, optionally with 1 to 2 C _{1 - 3} alkyl or C (O) C _1-3-amino which may be substituted by alkyl, cyano or COOR ";

In this case, C ₁ contained in the above as substituent or substituents _{- 6} alkyl optionally may be substituted with 1 to 3 halogen, R ', R "are independently hydrogen or alkyl of C _{1 -6.}

The term " halogen ", as used herein, unless otherwise indicated, means fluorine, chlorine, bromine or iodine.

The term " alkyl ", as used herein, unless otherwise indicated, means a saturated monovalent hydrocarbon compound having straight or branched moieties.

In the triazolyl salicylamide derivative of the formula (1) according to the present invention,

R ² is hydrogen, halogen, C _{1 - 3} alkyl, OC _{1 - 3} alkyl, or COOR 'and;

Ar is thiophenyl, imidazolyl, pyridinyl or phenyl substituted or unsubstituted with 1 to 3 of X;

X is hydrogen, halogen, C _{1 - 3} alkyl, OC _{1 - 3} alkyl, and optionally one to two of the CH ₃ or C (O) amino which may be substituted by CH _3, cyano or COOR "and;

In this case, the C _{1 - 3} alkyl optionally may be substituted with 1 to 3 halogen, R ', R "is independently may be hydrogen or alkyl of C _{1 -3.}

Further, in the triazolyl salicylamide derivative of the above formula (I)

R ² is hydrogen, chloro, bromo, fluoro, CH ₃ , CF ₃ , OCH ₃ , COOH or COOCH ₃ ;

Ar is selected from the group consisting of 3,5-dimethoxyphenyl, 3,5-bis (trifluoromethyl) phenyl, 3,5-difluorophenyl, dimethylaminophenyl, cyanophenyl, 5-chloro-2,4- Phenyl, chlorophenyl, methoxycarbonylphenyl, tolyl, fluorophenyl, pyridinyl, thiophenyl, acetaminophenyl, pyridinyl, 1-methyl-1H-imidazol-5-yl or carboxyphenyl.

Further, in a preferred embodiment, the triazolyl salicylamide derivative of Formula 1 may be a compound represented by Formula 2 below:

(2)

Wherein R ¹ and R ² are as defined in claim 1.

Also preferably, R ² can be hydrogen, chloro, CH ₃ , OCH ₃ , CF ₃ , COOH or COOCH ₃ .

In yet another preferred embodiment, the triazolyl salicylamide derivative of Formula 1 may be a compound represented by Formula 3:

(3)

In the above formula, Ar is as defined in the above formula (1).

Preferably, Ar is selected from the group consisting of 3,5-bis (trifluoromethyl) phenyl, 3,5-difluorophenyl, dimethylaminophenyl, cyanophenyl, 5-chloro-2,4-dimethoxyphenyl, chlorophenyl, Methoxycarbonylphenyl, tolyl, fluorophenyl, pyridinyl, thiophenyl, acetaminophenyl, pyridinyl, 1-methyl-1H-imidazol-5-yl or carboxyphenyl.

Specific examples of the more preferable compound of the above-mentioned formula (1) are as follows.

(1) 3- (4- (3,5-dimethoxyphenyl) -1 H -1,2,3- triazol-1-yl) - N - (3- (trifluoromethyl) phenyl) benzamide (2a);

(2) 5- (4- (3,5-dimethoxyphenyl) -1 H -1,2,3- triazol-1-yl) -2-hydroxy - N - phenyl-benzamide (2b);

(3) 5- (4- (3,5-dimethoxyphenyl) -1 H -1,2,3- triazol-1-yl) -2-hydroxy - N - (m - tolyl) benzamide ( 2c);

(4) 5- (4- (3,5-dimethoxyphenyl l) -1 H -1,2,3- triazol-1-yl) -2-hydroxy - N - (3- methoxyphenyl) Benzamide (2d);

(5) Synthesis of N - (3-chlorophenyl) -5- (4- (3,5-dimethoxyphenyl) -1 H -1,2,3- triazol- 1 -yl) -2-hydroxybenzamide (2e);

(6) 5- (4- (3,5-dimethoxyphenyl) -1 H -1,2,3- triazol-1-yl) -2-hydroxy - N - (2- (trifluoromethyl ) Phenyl) benzamide (2f);

(7) Synthesis of methyl 3- (5- (4- (3,5-dimethoxyphenyl) -1 H -1,2,3-triazol-1-yl) -2-hydroxybenzamido) benzoate 2g);

(8) 5- (4- (3,5-bis (trifluoromethyl) phenyl) -1 H -1,2,3- triazol-1-yl) -2-hydroxy - N - (3- (Trifluoromethyl) phenyl) benzamide (3a);

(9) 5- (4- (3,5-difluorophenyl) -1 H -1,2,3- triazol-1-yl) -2-hydroxy - (3- (trifluoro-N Methyl) phenyl) benzamide (3b);

(10) 5- (4- (4- (dimethylamino) phenyl -1 H -1,2,3- triazol-1-yl) -2-hydroxy - N - methyl (3- (trifluoromethyl) Phenyl) benzamide (3c);

(11) 5- (4- (4-cyanophenyl) -1 H -1,2,3- triazol-1-yl) -2-hydroxy - N - (3- (trifluoromethyl) phenyl ) Benzamide (3d);

12 5- (4- (5-chloro-2,4-dimethoxyphenyl) -1 H -1,2,3- triazol-1-yl) -2-hydroxy - N - (3- ( Trifluoromethyl) phenyl) benzamide (3e);

(13) 5- (4- (3-chlorophenyl) -1 H -1,2,3- triazol-1-yl) -2-hydroxy - N - (3- (trifluoromethyl) phenyl) Benzamide (3f);

(14) Synthesis of methyl 4- (1- (4-hydroxy-3 - ((3- (trifluoromethyl) phenylcarbamoyl) phenyl-1 H -1,2,3- triazol- Benzoate (3 g);

(15) 2-hydroxy -5- (4- (m - tolyl) -1 H -1,2,3- triazol-1-yl) - N - (3- (trifluoromethyl) phenyl) benzamide Amide (3h);

(16) 2-hydroxy -5- (4- (p - tolyl) -1 H -1,2,3- triazol-1-yl) - N - (3- (methyl sul ㅌ reflow Luo) phenyl ) Benzamide (3i);

(17) 5- (4- (4-fluorophenyl) -1 H -1,2,3- triazol-1-yl) -2-hydroxy - N - (3- (trifluoromethyl) phenyl ) Benzamide (3j);

(18) Synthesis of 2-hydroxy-5- (4- (pyridin-3-yl) -1H-1,2,3- triazol- Benzamide (3k);

(19) 2-hydroxy-5- (4- (thiophen-3-yl) -1 H -1,2,3- triazol-1-yl) - N - (3- (trifluoromethyl) Phenyl) benzamide (31);

20. 5- (4- (3-acetamido-phenyl) -1 H -1,2,3- triazol-1-yl) -2-hydroxy - N - (3- (trifluoromethyl) Phenyl) benzamide (3m);

(21) Synthesis of methyl 3- (1- (4-hydroxy-3 - ((3- (trifluoromethyl) phenylcarbamoyl) phenyl) -1 H -1,2,3- triazol- ) Benzoate (3n);

(22) 2-hydroxy-5- (4- (pyridin-2-yl) -1 H -1,2,3- triazol-1-yl) - N - methyl (3- (trifluoromethyl) phenyl ) ≪ / RTI > benzamide (3o);

(23) 2-hydroxy-5- (4- (1-methyl -1 H - imidazol-5) -1 H -1,2,3- triazol-1-yl) - N - (3 - (trifluoromethyl) phenyl) benzamide (3p);

(24) 3- (5- (4- (3,5-Dimethoxyphenyl) -1 H -1,2,3-triazol-1-yl) -2- hydroxybenzamido) benzoic acid (2h) ;

(25) Synthesis of 4- (1- (4-hydroxy-3 - ((3- (trifluoromethyl) phenylcarbamoyl) phenyl-1 H -1,2,3- triazol- (3q);

(26) 3- (1- (4-Hydroxy-3 - ((3- (trifluoromethyl) phenylcarbamoyl) phenyl) -1 H- 1,2,3- triazol- Benzoic acid (3r).

The compound of formula (1) according to the present invention can be prepared, for example, by the method shown in the following reaction formula (1).

[Reaction Scheme 1]

Wherein R ¹ and R ² are as defined in the above formula (1).

Specifically, as shown in Scheme 1, first, a building block of azide containing a benzamide group or a salicylamide group was prepared, and then a Cu (I) -catalyzed azide-alkyne 1,3-dipolar cycloaddition (CuAAC) Lt; RTI ID = 0.0 > 1-ethynyl-3,5-dimethoxybenzene. ≪ / RTI > The synthesis of the azidobenzamide of formula (7a) and the azidesaryl amide of formula (7b-7h) can be prepared from commercially available 3-aminobenzoic acid (4a) or 5-aminosalicylic acid (4b). Aminobenzoic acid of formula 4a or 4b or an H ₂ SO ₄ solution of 5-aminosalicylic acid is added to an aqueous solution of NaNO ₂ to produce a diazonium salt which is then treated with NaN ₃ to give the compounds of formulas 5a and 5b . Subsequently, the coupling reaction is carried out using substituted anilines (Formula 6a to 6g) in the presence of 1,1'-carbonyldiimidazole to obtain the azidobenzamide of Formula 7a and the azidesarylsilane of Formula 7b to 7h Amide compound is obtained. Then, the compound according to the present invention performed the click reaction in the presence of CuSO _4, ascorbic acid, sodium and alkynyl in the solvent such as the optimization of the compound of Preparation 7a-7b standard Click reaction conditions as t-BuOH / H ₂ O ≪ / RTI > At this time, the compound of formula (2h) can be synthesized by hydrolysis of 2g of the corresponding methyl benzoate analog.

On the other hand, as an example of another method for producing the compound according to the present invention, 1,2,3-triazolyl salicylate of formula (III) having a moiety N- (3- (trifluoromethyl) phenyl) The preparation of the amide derivatives can be carried out by the following reaction formula (2).

[Reaction Scheme 2]

Wherein Ar is as defined in the above formula (1).

As in Scheme 2 above, the CuAAC reaction is first performed using a variety of aromatic alkynes as azithosalicylamide of Formula 7h and an alkyne coupling partner as an azide coupling partner. All reactions under standard cyclic reaction conditions can produce 1,2,3-triazolyl salicylamide of formulas 3a to 3p in a yield of 27 to 99%. In addition, the benzoic acid analogues of formulas 3q and 3r can be prepared through the saponification reaction of the methyl ester compounds of formulas 3g and 3n.

The compounds of formulas (1) to (3) according to the present invention can be used in the form of pharmaceutically acceptable salts derived from inorganic or organic acids. Preferred salts thereof include hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, acetic acid, Examples of the organic acid include acetic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, malic acid, mandelic acid, tartaric acid, citric acid, ascorbic acid, palmitic acid, maleic acid, Salicylic acid, methanesulfonic acid, benzenesulfonic acid or toluenesulfonic acid, and the like.

Since the triazolyl salicylamide derivative or the pharmaceutically acceptable salt thereof according to the present invention effectively inhibits the action of aurora kinase, the pharmaceutical composition comprising it as an active ingredient can be used for the treatment of a disease associated with the activity of aurora kinase, Prevention of cancer, such as the digestive organs such as the pancreas, lungs, digestive organs such as the brain, reproductive organs, colon, urinary tract, eye, liver, skin, head and neck, And can exhibit useful therapeutic effects. Furthermore, the triazolyl salicylamide derivative according to the present invention or a pharmaceutically acceptable salt thereof can be co-administered with other anticancer drugs to enhance the therapeutic effect of the anticancer drug. That is, the compound according to the present invention or a pharmaceutically acceptable salt thereof may be used in combination with a cell signaling inhibitor, a mitotic inhibitor, an alkylating agent, an anti-metabolite, an insertion antibiotic, a growth factor inhibitor, a cell cycle inhibitor, a topoisomerase inhibitor, Is useful for raising the effectiveness of anticancer agents used in the treatment of cancer or other diseases selected from the group consisting of modulators, anti-hormones, and anti-androgens.

Accordingly, the present invention provides a pharmaceutical composition for preventing or treating Aurora kinase-related diseases, which comprises, as an active ingredient, triazolyl salicylamide of the formula (1) or a pharmaceutically acceptable salt thereof. The dosage of the active ingredient, such as a compound of the present invention or a pharmaceutically acceptable salt thereof, depends on the subject to be treated, the severity of the disease or condition, the rate of administration and the judgment of the prescribing physician. As an active ingredient, triazolyl salicylamide of the formula (I) is administered to a mammal comprising a human in an amount of 1 to 90 mg / kg (body weight), preferably 1 to 20 mg / kg (body weight) It may be administered via oral or parenteral routes with a schedule or on / off schedule. In some cases, dosage values less than the above-mentioned ranges may be more suitable, more doses may be used without causing harmful side effects, and more doses may be administered several times daily / RTI >

The pharmaceutical composition according to the present invention may be formulated according to a conventional method and may be formulated into various oral dosage forms such as tablets, pills, powders, capsules, syrups, emulsions and microemulsions or non-excipients such as intramuscular, intravenous or subcutaneous administration May be formulated in oral administration forms.

When the pharmaceutical composition of the present invention is prepared in the form of an oral formulation, examples of the carrier to be used include cellulose, calcium silicate, corn starch, lactose, sucrose, dextrose, calcium phosphate and stearic acid, magnesium stearate, calcium stearate , Gelatin, talc, a surfactant, a suspending agent, an emulsifier, and a diluent. When the pharmaceutical composition of the present invention is prepared in the form of an injectable preparation, the carrier may include water, saline solution, aqueous glucose solution, pseudosugar solution, alcohol, glycol, ether (e.g., polyethylene glycol 400), oil, fatty acid, fatty acid ester, glyceride , Surfactants, suspending agents, and emulsifiers.

The novel triazolyl salicylamide derivatives of the present invention are useful for the prophylaxis or treatment of diseases related to Aurora kinase, for example various cancers, due to their excellent inhibitory effect on Aurora kinase.

Hereinafter, the present invention will be described in more detail by way of examples. However, the following examples are illustrative of the present invention and are not intended to limit the scope of the present invention.

Example

All reactions were carried out in a flame-dried glass vessel fitted with a glass stopper under argon static pressure, using a magnetic stirrer, unless otherwise stated. Air- and moisture-sensitive liquids and solutions were transferred through injections or stainless steel-steel cannulas. TLC was performed on a 0.25 mm E. Merck silica gel 60 F ₂₅₄ plate and visualized under ultraviolet light (254 nm) or dyed using potassium ammonium molybdate (CAM), potassium permanganate (KMnO ₄ ), p -aniside . Flash chromatography was performed on E. Merck 230-400 mesh silica gel 60. All reagents were purchased from commercial suppliers and were not further purified unless otherwise noted. The solvent was distilled under argon gas at 760 mm Hg using a suitable drying agent (CaH ₂ or Na wire). All water- and / or oxygen-sensitive solids were handled and stored in a glovebox under nitrogen (N ₂ ). NMR spectra were recorded on Varian Unity 400 instruments at 24 < 0 > C. Chemical shifts were expressed in ppm for TMS (1H, O ppm), CDCl ₃ (1H, 7.26 ppm; 13C, 77.2 ppm) and coupling constants in Hz. High resolution mass spectra electrospray ionization (HRMS-ESI) was obtained on an Agilent technologies 6220 TOF LC / MS spectrometer or JEOL JMS-600W 70 eV (Electron Ionization).

Manufacturing example  One: Azide  General process of synthesis of compound (Formula 5)

A solution of the compound of formula 4 (36.0 mmol) in H ₂ SO ₄ (27 mL) and H ₂ O (144 mL) was added to a NaNO ₂ solution (43.2 mmol) in H ₂ O (27 mL) at 0 ° C. After stirring at 0 ℃ for 1.5 h, it was added dropwise NaN ₃ (61.2 mmol) solution in H ₂ O (22 mL) at 0 ℃. The resulting suspension was stirred at 0 < 0 > C for 1.5 h and at ambient temperature for 15 h. After the reaction was complete, the mixture was extracted with EtOAc (5 x 100 mL). After washing the combined organic extracts with brine (brine), dried over anhydrous MgSO _4, filtered and evaporated to give an azide of formula (5).

Manufacturing example  1-1: 3- Of the azabenzoic acid (5a)  Produce

(5.00 g, 36.0 mmol), NaNO ₂ (3.00 g, 43.2 mmol) and NaN ₃ (4.00 g, 61.2 mmol) were used according to the general method for the general formula 5, . The resulting suspension was stirred at 0 < 0 > C for 1.5 h and at room temperature for 15 h to give the azide (5a) as a gray solid (5.87 g, 100%).

_{TLC: R f 0.22 (20:} 1 CH 2 Cl 2 / MeOH). ^{1 H-NMR (400 MHz,} CDCl 3): δ 7.90 (ddd, J = 8.0, 2.4, 1.6 Hz, 1H), 7.78 (dd, J = 2.4, 1.6 Hz, 1H), 7.48 (t, J = 8.0 Hz, 1 H) 7.27 (ddd, J = 8.0, 2.4, 1.6 Hz, 1 H). ^{13 C-NMR (100 MHz,} DMSO- d 6): δ 166.4, 139.9, 132.6, 130.3, 125.8, 123.5, 119.4. _{HRMS m / z calcd for C 7} H 5 N 3 O 2 163.0382; found 163.0384.

Manufacturing example  1-2: 5- Azido -2- Hydroxybenzoic acid  (5b)

Using the 5-aminosalicylic acid (4b) (15.4 g, 100 mmol), NaNO ₂ (8.32 g, 120 mmol) and NaN ₃ (11.1 g, 170 mmol) . The resulting suspension was stirred at 0 < 0 > C for 1.5 hours, at ambient temperature for 13 hours to give the compound of formula (5b) as a reddish brown solid (17.5 g, 98%

_{TLC: R f 0.43 (5:} 1 EtOAc / MeOH). ^{1 H-NMR (400 MHz,} DMSO- d 6): δ 11.24 (br s, 1H), 7.42 (d, J = 2.8 Hz, 1H), 7.28 (dd, J = 8.8, 2.8 Hz, 1H), 7.01 (d, J = 8.8 Hz, 1H). ^{13 C-NMR (100 MHz,} DMSO- d 6): δ 170.9, 158.3, 130.2, 126.6, 119.7, 118.9, 113.9. _{HRMS m / z calcd for C 7} H 5 N 3 O 3 179.0331; found 179.0332.

Manufacturing example  2: General method of synthesis of compound of formula (7)

(1.40 g, 7.50 mmol) and 1,1'-carbonyldiimidazole (1.40 g, 7.50 mmol) in anhydrous CH ₃ CN (5 mL, 5.00 mmol) and 3-azidobenzoic acid Lt; / RTI > The corresponding aniline compound (15.0 mmol) and triethylamine (1.00 mL, 7.50 mmol) were then added at 80 < 0 > C. The resulting solution was stirred at 80 < 0 > C for 24 hours. After the reaction was complete, the reaction mixture was diluted with CH ₂ Cl ₂ (200 mL), neutralized using 1 N HCl (200 mL), stirred at room temperature for 30 min, washed with CH ₂ Cl ₂ mL). The combined organic extracts were dried using anhydrous MgSO ₄ , filtered and concentrated by rotary evaporation. The residue was purified by column chromatography to give compound 7. < 1 >

Manufacturing example  2-1: 3- Azido - N - (3- ( Trifluoromethyl ) Phenyl ) Benzamide  (7a)

Following the general method for the general formula (7), in anhydrous CH ₃ CN (6 mL) 3- O map acid (5a) in a (816 mg, 5.00 mmol), 1,1'- carbonyldiimidazole 90% (1.40 imidazole g, 7.50 mmol), 3- (trifluoromethyl) aniline (6a) (1.90 mL, 15.0 mmol) and triethylamine (1.00 mL, 7.50 mmol). The reaction mixture was stirred at 80 < 0 > C for 24 hours. Column chromatography (4: 1 hexane / EtOAc) provided compound 7a as a brown solid (1.40 g, 91%).

_{TLC: R f 0.38 (4:} 1 hexane / EtOAc). ^{Mp: 110-112 o C. 1 H-} NMR (400 MHz, CDCl 3): δ 7.94 (s, 1H), 7.87-7.85 (m, 2H), 7.60 (ddd, 1H, J = 7.6, 1.6, 0.8 Hz), 7.56 (t, J = 2.0 Hz, 1H), 7.53-7.48 (m, 2H), 7.43 (d, J = 7.6 Hz, 1H), 7.24 (ddd, J = 7.6, 2.0, 0.8 Hz, 1H ). ^{13 C-NMR (100 MHz,} CDCl 3): δ 164.9, 139.9, 139.7, 136.1, 130.2, 129.9, 129.2 (q, J C -F = 31.5 Hz), 124.4, 124.1 (q, J C -F = 271.0 Hz), 123.9, 122.5, 120.1 (q, J C -F = 3.6 Hz), 118.2, 116.5 (q, J C -F = 3.6 Hz). _{HRMS m / z calcd for C 14} H 3f3 N 4 O 306.0728; found 306.0730.

Manufacturing example  2-2: 5- Azido -2- Hydroxy - N - Phenylbenzamide  (7b)

Following the general method for the general formula (7), in anhydrous CH ₃ CN (6 mL) in a 5-azido-2-hydroxy benzoic acid (5b) (896 mg, 5.00 mmol), 1,1'- carbonyldiimidazole imidazole (1.40 g, 7.50 mmol), aniline (6b) (1.40 mL, 15.0 mmol), and triethylamine (1.00 mL, 7.50 mmol). The reaction mixture was stirred at 80 < 0 > C for 2 hours. Column chromatography (4: 1 hexane / EtOAc) provided compound 7b as a brown solid (537 mg, 42%).

_{TLC: R f 0.37 (3:} 1 hexane / EtOAc). ^{Mp: 160-162 o C. 1 H-} NMR (400 MHz, CDCl 3): δ 11.76 (. S 1H), 7.81 (br s, 1H), 7.58 (d, J = 7.6 Hz, 2H), 7.42 ( t, J = 7.6 Hz, 2H ), 7.23 (t, J = 7.6 Hz, 1H), 7.19 (dd, J = 8.8, 2.8 Hz, 1H), 7.10 (d, J = 2.8 Hz, 1H), 7.06 ( d, J = 8.8 Hz, 1H). ^{13 C-NMR (100 MHz,} DMSO- d 6): δ 165.2, 155.5, 138.0, 130.3, 128.7, 124.4, 124.3, 120.9, 119.2, 118.9, 118.8. _{HRMS m / z calcd for C 13} H 10 N 4 O 2 254.0804; found 254.0801.

Manufacturing example  2-3: 5- Azido -2- Hydroxy - N - m - Tolylbenzamide  (7c)

Following the general method for the general formula (7), in anhydrous CH ₃ CN (3.50 mL) in a 5-azido-2-hydroxy benzoic acid (5b) (500 mg, 2.80 mmol), 1,1'- carbonyldiimidazole already The target compound was prepared using 90% (90%) of dodecanol (780 mg, 4.10 mmol), m -tolylamine (6c) (1.00 mL, 8.37 mmol) and triethylamine (560 μL, 4.10 mmol). The reaction mixture was stirred at 80 < 0 > C for 2.5 hours. Column chromatography (6: 1 hexane / EtOAc) provided 7c as a yellow solid (460 mg, 61%).

_{TLC: R f 0.44 (4:} 1 hexane / EtOAc). ^{Mp: 141-143 o C. 1 H-} NMR (400 MHz, DMSO- d 6): δ 11.81 (br s, 1H), 10.40 (s, 1H), 7.68 (d, J = 2.8 Hz, 1H), 7.52 (s, 1H), 7.49 (d, J = 7.6 Hz, 1H), 7.25 (t, J = 7.6 Hz, 1H), 7.21 (dd, J = 8.8, 2.8 Hz, 1H), 7.04 (d, J = 8.8 Hz, 1H), 6.97 (d, J = 7.6 Hz, 1H), 2.32 (s, 3H). ^{13 C-NMR (100 MHz,} DMSO- d 6): δ 165.2, 155.5, 138.0, 137.9, 130.3, 128.6, 125.0, 124.4, 121.4, 119.2, 118.8, 118.7, 118.1, 21.1. _{HRMS m / z calcd for C 14} H 12 N 4 O 2 268.0960; found 268.0961.

Manufacturing example  2-4: 5- Azido -2- Hydroxy - N - (3- Methoxyphenyl ) Benzamide  (7d)

Following the general method for the general formula (7), in anhydrous CH ₃ CN (6 mL)-2-hydroxy-benzoic acid (5b) 5- charge in (896 mg, 5.00 mmol), 1,1'- carbonyldiimidazole already (1.40 g, 7.50 mmol), 3-methoxyaniline (6d) (1.70 mL, 15.0 mmol) and triethylamine (1.00 mL, 7.50 mmol).

The reaction mixture was stirred at 80 < 0 > C for 15 hours. Compound 7d was obtained in the form of a brown solid (738 mg, 52%) using column chromatography (4: 1 hexane / EtOAc).

_{TLC: R f 0.45 (5:} 1 hexane / EtOAc). ^{Mp: 145-147 o C. 1 H-} NMR (400 MHz, DMSO- d 6): δ 11.72 (br s 1H.), 10.59 (br s, 1H), 7.64 (d, J = 2.8 Hz, 1H) , 7.40 (t, J = 2.4 Hz, 1H), 7.28 (t, J = 7.6 Hz, 1H), 7.25-7.18 (m, 2H), 7.01 (d, J = 8.8 Hz, 1H), 6.72 (d, J = 7.6 Hz, 1 H), 3.76 (s, 3 H). ^{13 C-NMR (100 MHz,} DMSO- d 6): δ 165.2, 159.6, 155.3, 139.2, 130.4, 129.6, 124.4, 119.3, 119.2, 118.9, 113.1, 109.9, 106.6, 55.1. _{HRMS m / z calcd for C 14} H 12 N 4 O 3 284.0909; found 284.0911.

Manufacturing example  2-5: 5- Azido - N - (3- Chlorophenyl )-2- Hydroxybenzamide  (7e)

Following the general method for the general formula (7), in anhydrous CH ₃ CN (6 mL)-2-hydroxy-benzoic acid (5b) 5- charge in (896 mg, 5.00 mmol), 1,1'- carbonyldiimidazole already (1.40 g, 7.50 mmol), 3-chloroaniline (6e) (1.60 mL, 15.0 mmol) and triethylamine (1.00 mL, 7.50 mmol). The reaction mixture was stirred at 80 < 0 > C for 16 hours. Column chromatography (3: 1 hexane / EtOAc) provided 7e as a brown solid (78.5 mg, 5%).

_{TLCδ: R f 0.39 (3:} 1 hexane / EtOAc). ^{Mp: 156.5-158.5 o C. 1 H-} NMR (400 MHz, DMSO- d 6): 11.55 (. Br s 1H), 10.51 (s, 1H), 7.92 (t, J = 2.0 Hz, 1H), 7.65 -7.59 (m, 2H), 7.40 (t, J = 8.4 Hz, 1H), 7.21-7.19 (m, 2H), 7.05 (d, J = 8.4 Hz, 1H). ^{13 C-NMR (100 MHz,} DMSO- d 6): δ 165.9, 155.7, 140.3, 133.8, 131.2, 131.1, 131.0, 125.1, 124.6, 120.9, 120.1, 119.8, 119.5. HRMS m / z: calcd for C 13 H 3c lN 4 O 2 288.0414; found 288.0419.

Manufacturing example  2-6: 5- Azido -2- Hydroxy - N -(2-( Trifluoromethyl ) Phenyl ) Benzamide  (7f)

Following the general method for the general formula (7), in anhydrous CH ₃ CN 5- azido-2-hydroxy benzoic acid (5b) in the (6 mL) (896 mg, 5.00 mmol), 1,1'- carbonyldiimidazole The target compound was prepared using 90% (1.40 g, 7.50 mmol), 2- (trifluoromethyl) aniline (6f) (1.90 mL, 15.0 mmol) and triethylamine (1.00 mL, 7.50 mmol). The reaction mixture was stirred at 80 < 0 > C for 24 hours. Column chromatography (3: 1 hexane / EtOAc) provided 7f as a brown solid (280 mg, 17%).

_{TLC: R f 0.17 (5:} 1 hexane / EtOAc). ^{Mp: 129.5-131.5 o C. 1 H-} NMR (400 MHz, DMSO- d 6): δ 12.06 (br s, 1H), 10.82 (br s, 1H), 8.19 (d, J = 8.0 Hz, 1H) , 7.83-7.73 (m, 2H), 7.12 (d, J = 2.8 Hz, 1H), 7.42 (t, J = 8.0 Hz, 1H), 7.25 (dd, J = 8.8, 2.8 Hz, 1H) d, J = 8.8 Hz, 1H). ^{13 C-NMR (100 MHz,} DMSO- d 6): δ 163.7, 154.3, 135.2, 133.3, 130.9, 126.2, 126.1, 125.4, 125.0, 123.8 (q, J C -F = 271.7 Hz), 120.9 (q, J _{C -F} = 29.3 Hz), 120.2, 118.8, 118.6. _{HRMS m / z calcd for C 14} H 3f3 N 4 O 2 322.0678; found 322.0682.

Manufacturing example  2-7: 3- (5- Azido -2- Hydroxybenzoylamino ) Benzoic acid methyl  Preparation of ester (7 g)

According to the general method for the above formula 7, 5-azido-2-hydroxybenzoic acid (5b) (896 mg, 5.00 mmol) in anhydrous CH ₃ CN (7.5 mL), 1,1'-carbonyldiimidazole The objective compound was prepared using 97% (1.25 g, 7.50 mmol), 3-aminobenzoic acid methyl ester (6 g) (2.27 g, 15.0 mmol) and triethylamine (1.00 mL, 7.50 mmol). The reaction mixture was stirred at 80 < 0 > C for 16 hours. Column chromatography (4: 1 hexane / EtOAc) provided 7 g (332 mg, 21%) of the compound as a brown solid.

_{TLC: R f 0.11 (5:} 1 hexane / EtOAc). ^{Mp: 160-162 o C. 1 H-} NMR (400 MHz, DMSO- d 6): δ 11.61 (br s 1H.), 10.76 (br s, 1H), 8.40 (t, J = 1.6 Hz, 1H) , 7.94 (dm, J = 8.0 Hz, 1H) 7.73 (dt, J = 8.0, 1.6 Hz, 1H), 7.65 (d, J = 2.8 Hz, 1H), 7.53 (t, J = 8.0 Hz, 1H), 7.21 (dd, J = 8.8,2.8 Hz, 1H), 7.03 (d, J = 8.8 Hz, 1H) 3.88 (s, 3H). ^{13 C-NMR (100 MHz,} DMSO- d 6): δ 166.0, 165.5, 155.4, 138.5, 130.4, 130.2, 129.3, 125.3, 124.8, 124.5, 121.2, 119.3, 119.0, 118.8. 52.2 HRMS m / z calcd for C 15 H 12 N 4 O 4 312.0859; found 312.0856.

Manufacturing example  2-8: 5- Azido -2- Hydroxy - N - (3- ( Trifluoromethyl ) Phenyl ) Benzamide  (7h)

Following the general method for the general formula (7), in anhydrous CH ₃ CN 5- azido-2-hydroxy benzoic acid (5b) in the (11 mL) (1.79 g, 10.0 mmol), 1,1'- carbonyldiimidazole The objective compound was prepared using 97% (2.70 g, 15.0 mmol) and 3- (trifluoromethyl) aniline (6a) (3.80 mL, 30.0 mmol) and triethylamine (2.1 mL, 15.0 mmol). The reaction mixture was stirred at 80 < 0 > C for 13.5 hours. Column chromatography (6: 1 hexane / EtOAc) provided 7 h as a yellow solid (700 mg, 22%).

_{TLC: R f 0.40 (4:} 1 hexane / EtOAc). ^{Mp: 149-151 o C. 1 H-} NMR (400 MHz, DMSO- d 6): δ 11.50 (br s, 1H), 11.04 (br s, 1H), 8.22 (s, 1H), 7.97 (d, J = 7.6 Hz, 1H), 7.62 (t, J = 7.6 Hz, 1H), 7.59 (d, J = 2.8 Hz, 1H), 7.48 (d, J = 7.6 Hz, 1H), 7.19 (dd, J = 8.8, 2.8 Hz, 1 H), 7.01 (d, J = 8.8 Hz, 1 H). ^{13 C-NMR (100 MHz,} DMSO- d 6): δ 165.5, 155.1, 138.9, 130.4, 129.9, 129.5 (q, J C -F = 31.6 Hz), 124.4, 124.3, 124.1 (d, J C -F = 270.3 Hz), 120.5 (d, J _{C -F} = 3.8 Hz), 119.3, 119.2 , 118.8, 116.8, (d, J C -F = 3.7 Hz). _{HRMS m / z calcd for C 14} H 3f3 N 4 O 2 322.0678; found 322.0674.

Example  1: Synthesis of Compounds of Formulas 2 and 3 [ Click Reaction ]

Azide compound of formula 7 (300 μmol), alkynyl _{(750 μmol), CuSO 4 (} 9.6 mg, 60 μmol) and Na. ascorbate (60.0 mg, 300 μmol) was dissolved in 1: 1 t- BuOH / H ₂ O (3 mL). The mixture was stirred at room temperature for 2 hours. After the reaction was complete, the mixtures were filtered and washed with H ₂ O (70 mL) (solid A). The filtrate was extracted with EtOAc (3 x 70 mL). The combined organic extracts were dried using anhydrous MgSO ₄ , filtered and concentrated by rotary evaporation (residue B). The solid A and the residue B were combined and purified by column chromatography to obtain the compounds of formulas (2) and (3).

Example  1-1: 3- (4- (3,5- Dimethoxyphenyl )-One H -1,2,3- Triazole -1 day)- N - (3- ( Trifluoromethyl ) Phenyl ) Benzamide  (2a)

Following the general method for the general formula 2, 1: 1 t -BuOH / H 2 O (3 mL) Compound 7a (95.8 mg, 300 μmol) , -3,5- dimethoxybenzene ethynyl-1-in (121 mg , 750 μmol), CuSO ₄ (9.6 mg, 60 μmol) and Na. ascorbate (60.0 mg, 300 μmol) was used to prepare the target compound. The reaction mixture was stirred at room temperature for 2 hours and then Compound 2a was obtained in the form of a brown solid (138 mg, 98%) using column chromatography (5: 1 hexane / EtOAc → 40: 1 CH ₂ Cl ₂ / MeOH) %).

_{TLC: R f 0.58 (20:} 1 CH 2 Cl 2 / MeOH). ^{Mp: 160-162 o C. 1 H-} NMR (400 MHz, DMSO- d 6): δ 10.79 (br s, 1H), 9.47 (s, 1H), 8.54 (t, J = 2.0 Hz, 1H), 8.27 (s, 1H), 8.20 (dm, J = 8.0 Hz, 1H), 8.11 (d, J = 8.0 Hz, 1H), 8.09 (d, J = 8.0 Hz, 1H), 7.84 (t, J = 8.0 Hz, 1H), 7.64 (t , J = 8.0 Hz, 1H), 7.50 (d, J = 8.0 Hz, 1H), 7.16 (d, J = 2.0 Hz, 2H), 6.54 (t, J = 2.0 Hz, 1H), 3.83 (s, 6H). ^{13 C-NMR (100 MHz,} DMSO- d 6): δ 164.8, 161.0, 147.4, 139.7, 136.7, 136.2, 131.9, 130.3, 130.0, 129.4 (d, J C -F = 30.8 Hz), 127.8, 124.2 ( d, J _{C -F} = 270.0 Hz), 123.9, 123.1, 120.2, 119.2, 116.5, 116.4, 103.3, 100.3, 55.3. HRMS m / z calcd for C ₂₄ H ₁₃ F ₃ N ₄ O ₃ 468.1409; found 468.1410.

Example  1-2: 5- (4- (3,5- Dimethoxyphenyl )-One H -1,2,3- Triazole Yl) -2- Hydroxy - N - Phenylbenzamide  (2b)

Following the general method for the general formula 2, 1: 1 t -BuOH / H 2 O (3 mL) Compound 7b (76.7 mg, 300 μmol) , -3,5- dimethoxybenzene ethynyl-1-in (121 mg , 750 μmol), CuSO ₄ (9.6 mg, 60 μmol) and Na. ascorbate (60.0 mg, 300 μmol) was used to prepare the target compound. The reaction mixture was stirred at room temperature for 48 hours and then Compound 2b was obtained in the form of a brown solid using column chromatography (5: 1 hexane / EtOAc to 20: 1 CH ₂ Cl ₂ / MeOH) (90.6 mg, 73 %).

_{TLC: R f 0.48 (20:} 1 CH 2 Cl 2 / MeOH). ^{Mp: 202-204 o C. 1 H-} NMR (400 MHz, DMSO- d 6): δ 11.97 (s, 1H), 10.55 (br s, 1H), 9.28 (s, 1H), 8.41 (d, J = 2.8 Hz, 1H), 7.97 (dd, J = 2.8, 8.8 Hz, 1H), 7.74 (d, J = 7.6 Hz, 2H), 7.40 (t, J = 7.6 Hz, 2H), 7.22 (d, J = 8.8 Hz, 1H), 7.17 (t, J = 7.6 Hz, 1H), 7.14 (d, J = 2.0 Hz, 2H), 6.52 (t, J = 2.0 Hz, 1H), 3.82 (s, 6H). ^{13 C-NMR (100 MHz,} DMSO- d 6): δ 164.9, 160.9, 157.7, 147.1, 138.1, 132.1, 128.8, 128.7, 125.2, 124.3, 121.2, 120.7, 120.1, 119.5, 118.4, 103.2, 100.2, 55.3 . HRMS m / z calcd for C ₂₃ H ₂₀ N ₄ O ₄ 416.1485; found 416.1487.

Example  1-3: 5- (4- (3,5- Dimethoxyphenyl )-One H -1,2,3- Triazole Yl) -2- Hydroxy - N - ( m - tolyl) Benzamide  (2c)

Following the general method for the general formula 2, 1: 1 t -BuOH / H 2 O (3 mL) Compound 7c (80.8 mg, 300 μmol) , -3,5- dimethoxybenzene ethynyl-1-in (121 mg , 750 μmol), CuSO ₄ (9.6 mg, 60 μmol) and Na. ascorbate (60.0 mg, 300 μmol) was used to prepare the target compound. The reaction mixture was stirred at room temperature for 5.5 hours and then Compound 2c was obtained in the form of a brown solid (104 mg, 80%) using column chromatography (5: 1 hexane / EtOAc to 20: 1 CH ₂ Cl ₂ / MeOH) ).

_{TLC: R f 0.48 (20:} 1 CH 2 Cl 2 / MeOH). ^{Mp: 204-206 o C. 1 H-} NMR (400 MHz, DMSO- d 6): δ 12.00 (br s, 1H), 10.48 (br s, 1H), 9.27 (s, 1H), 8.42 (d, J = 2.8 Hz, 1H), 7.97 (dd, J = 8.8, 2.8 Hz, 1H), 7.56 (s, 1H), 7.54 (d, J = 7.6 Hz, 1H), 7.28 (t, J = 7.6 Hz, 1H), 7.22 (d, J = 8.8 Hz, 1H), 7.14 (d, J = 2.4 Hz, 2H), 6.98 (d, J = 7.6 Hz, 1H), 6.52 (t, J = 2.4 Hz, 1H) , 3.82 (s, 6 H), 2.33 (s, 3 H). ^{13 C-NMR (100 MHz,} DMSO- d 6): δ 164.8, 162.0, 160.9, 157.8, 147.1, 138.1, 138.0, 132.1, 128.7, 128.6, 125.3, 125.0, 121.2, 120.1, 119.4, 118.4, 117.9, 103.2 , 100.2, 55.3, 21.1. HRMS m / z calcd for C ₂₄ H ₂₂ N ₄ O ₄ 430.1631; found 430.1634.

Example  1-4: 5- (4- (3,5- Dimethoxyphenyl l) -1 H -1,2,3- Triazole Yl) -2- Hydroxy - N - (3- Methoxyphenyl ) Benzamide  (2d)

Following the general method for the general formula 2, 1: 1 t -BuOH / H 2 O (3 mL) Compound 7d (85.3 mg, 300 μmol) , -3,5- dimethoxybenzene ethynyl-1-in (121 mg , 750 μmol), CuSO ₄ (9.6 mg, 60 μmol) and Na. ascorbate (60.0 mg, 300 μmol) was used to prepare the target compound. The reaction mixture was stirred at 40 ℃ for 47 hours, was purified by column chromatography (5: 1 hexane / EtOAc → 20: 1 CH 2 Cl 2 / MeOH) Compound 2d was obtained using as a brown solid (98.8mg, 74%).

TLC: R _f 0.50 (20: 1 CH ₂ Cl ₂ / MeOH). ^{Mp: 183-185 o C. 1 H-} NMR (400 MHz, DMSO- d 6): δ 11.93 (br s, 1H), 10.67 (br s, 1H), 9.28 (s, 1H), 8.38 (d, J = 2.8 Hz, 1H), 7.95 (d, J = 8.8 Hz, 1H), 7.45 (t, J = 1.6 Hz, 1H), 7.29-7.28 (m, 2H), 7.19 (d, J = 8.8 Hz, 1H), 7.14 (d, J = 2.4 Hz, 2H), 6.73 (m, 1H), 6.51 (t, J = 2.4 Hz, 1H), 3.82 (s, 6H), 3.77 ^{13 C-NMR (100 MHz,} DMSO- d 6): δ 164.8, 161.0, 159.6, 157.5, 147.2, 139.3, 132.1, 129.6, 128.8, 125.2, 121.3, 120.1, 119.7, 118.4, 112.9, 109.8, 106.4, 103.2 , 100.2, 55.3, 55.1. HRMS m / z calcd for C ₂₄ H ₂₂ N ₄ O ₅ 446.1590; found 446.1592.

Example  1-5: N - (3- Chlorophenyl ) -5- (4- (3,5- Dimethoxyphenyl )-One H -1,2,3-triazol-1-yl) -2- Hydroxybenzamide  (2e)

Following the general method for the general formula 2, 1: 1 t -BuOH / H 2 O (3 mL) -3,5- dimethoxybenzene ethynyl compound 7e (29.5 mg, 100 μmol) , 1- in (40.6 mg , 250 μmol), CuSO ₄ (3.2 mg, 20 μmol) and Na. ascorbate (20.0 mg, 100 [mu] mol). The reaction mixture was stirred at room temperature for 66 hours and then Compound 2e was obtained in the form of a brown solid (23.1 mg, 51%) using column chromatography (5: 1 hexane / EtOAc to 30: 1 CH ₂ Cl ₂ / MeOH) %).

_{TLC: R f 0.47 (20:} 1 CH 2 Cl 2 / MeOH). ^{Mp: 226-228 o C. 1 H-} NMR (400 MHz, DMSO- d 6): δ 10.60 (brs, 1H), 9.09 (s, 1H), 8.29 (d, J = 2.0 Hz, 1H), 7.91 -7.87 (m, 2H), 7.54 (d, J = 8.0 Hz, 1H), 7.38 (t, J = 8.0 Hz, 1H), 7.17 (d, J = 8.0 Hz, 1H), 7.07 (d, J = 2.4 Hz, 2H), 7.00 (m, 1H), 6.47 (t, J = 2.4 Hz, 1H), 3.90 (s, 6H). ¹³ C-NMR (100 MHz, DMSO- d ₆ ): δ 165.5, 161.5, 157.9, 147.8, 140.0, 133.8, 132.4, 131.2, 129.3, 126.0, 124.7, 122.0, 120.7, 120.6, 120.2, 119.6, 119.0, 103.9 , 100.8, 55.9. HRMS m / z calcd for C ₂₃ H ₁₃ ClN ₄ O ₄ 450.1096; found 450.1096.

Example  1-6: 5- (4- (3,5- Dimethoxyphenyl )-One H -1,2,3- Triazole Yl) -2- Hydroxy - N -(2-( Trifluoromethyl ) Phenyl ) Benzamide  (2f)

(34.6 mg, 100 μmol), 1-ethynyl-3,5-dimethoxybenzene (40.1 mg, 1 mmol) in 1: 1 t- BuOH / H ₂ O , 250 μmol), CuSO ₄ (3.2 mg, 20 μmol) and Na. ascorbate (20.0 mg, 100 [mu] mol). The reaction mixture was stirred at room temperature for 3.5 h, purified by column chromatography (5: 1 hexane / EtOAc → 20: 1 CH 2 Cl 2 / MeOH) to give the compound 2f using as a brown solid (39.7mg, 82 %).

_{TLC: R f 0.47 (20:} 1 CH 2 Cl 2 / MeOH). ^{Mp: 188-190 o C. 1 H-} NMR (400 MHz, DMSO- d 6): δ 12.50 (br s, 1H), 10.87 (br s, 1H), 9.32 (s, 1H), 8.53 (d, J = 2.8 Hz, 1H), 8.25 (d, J = 8.0 Hz, 1H), 8.03 (dd, J = 8.8, 2.8 Hz, 1H), 7.80 (d, J = 8.0 Hz, 1H), 7.76 (t, J = 8.0 Hz, 1H), 7.43 (t, J = 8.0 Hz, 1H), 7.27 (d, J = 8.8 Hz, 1H), 7.15 (d, J = 2.4 Hz, 2H), 6.51 (t, J = 2.4 Hz, 1 H), 3.82 (s, 6 H). ^{13 C-NMR (100 MHz,} DMSO- d 6): δ 163.3, 160.9, 156.7, 147.2, 135.2, 133.4, 132.1, 129.3, 126.2, 126.0, 125.9, 125.4, 124.1 (q, J C -F = 270 Hz ), 122.3, 120.1, 118.6, 118.4, 103.3, 100.2, 99.3, 55.3. HRMS m / z calcd for C ₂₄ H ₁₃ F ₃ N ₄ O ₄ 484.1358; found 485.1354.

Example  1-7: methyl  3- (5- (4- (3,5- Dimethoxyphenyl )-One H -1,2,3- Triazole -1-yl) -2-hydroxybenzamido) Benzoate  (2 g)

According to the general method for the above formula 2, 7 g (31.2 mg, 100 μmol) of the compound in 1: 1 t- BuOH / H ₂ O (1 mL), 1-ethynyl-3,5-dimethoxybenzene , 250 μmol), CuSO ₄ (3.2 mg, 20 μmol) and Na. ascorbate (20.0 mg, 100 [mu] mol). The reaction mixture was stirred for 5 h at 60 [deg.] C and then ₂ g of the compound was obtained in the form of a brown solid using column chromatography (5: 1 hexane / EtOAc to 20: 1 CH ₂ Cl ₂ / MeOH) , 71%).

_{TLC: R f 0.12 (30:} 1 CH 2 Cl 2 / MeOH). ^{Mp: 273-275 o C. 1 H-} NMR (400 MHz, DMSO- d 6): δ 11.86 (br s, 1H), 10.79 (br s, 1H), 9.29 (s, 1H), 8.44 (t, J = 1.6 Hz, 1H), 8.41 (d, J = 2.8 Hz, 1H), 8.00 (m, 1H), 7.98 (dd, J = 2.8,8.8 Hz, 1H) t, J = 8.0 Hz, 1H ), 7.23 (d, J = 8.8 Hz, 1H), 7.14 (d, J = 2.4 Hz, 2H), 6.52 (t, J = 2.4 Hz, 1H), 3.88 (s, 3H), 3.82 (s, 6H). ^{13 C-NMR (100 MHz,} DMSO- d 6): δ 166.0, 165.3, 160.9, 157.9, 147.1, 138.6, 132.1, 130.2, 129.3, 128.6, 125.3, 125.2, 124.8, 121.7, 121.1, 120.2, 119.4, 118.4 , 103.2, 100.2, 55.3, 52.2. HRMS m / z calcd for C ₂₅ H ₂₂ N ₄ O ₆ 474.1539; found 474.1538.

Example  1-8: 5- (4- (3,5- Bis (trifluoromethyl) phenyl )-One H -1,2,3- Triazole Yl) -2- Hydroxy - N - (3- ( Trifluoromethyl ) Phenyl ) Benzamide  (3a)

Following the general method for the general formula (3), 1: Compound 7h (96.7 mg, 300 μmol) in _{1 t -BuOH / H 2 O (} 3 mL), methyl-3,5-bis (trifluoro-1-ethynyl ) benzene (133 μL, 750 μmol), CuSO 4 (9.6 mg, 60 μmol) and Na. ascorbate (59.4 mg, 300 [mu] mol). The reaction mixture was stirred at room temperature for 2.5 hours and then Compound 3a was obtained as an ivory solid (166 mg, 99%) using column chromatography (30: 1 CH ₂ Cl ₂ / MeOH).

_{TLC: R f 0.24 (3:} 1 hexane / EtOAc). ^{Mp: 194-196 o C. 1 H-} NMR (400 MHz, DMSO- d 6): δ 11.82 (br s, 1H), 10.75 (br s, 1H), 9.63 (s, 1H), 8.57 (s, 2H), 8.38 (d, J = 2.8 Hz, 1H), 8.25 (s, 1H), 8.10 (s, 1H), 7.99 (dd, J = 9.2, 2.8 Hz, 1H), 7.96 (d, J = 7.6 Hz, 1H), 7.62 (t , J = 7.6 Hz, 1H), 7.49 (d, J = 7.6 Hz, 1H), 7.25 (d, J = 9.2 Hz, 1H). ^{13 C-NMR (100 MHz,} DMSO- d 6): δ 164.9, 157.3, 144.5, 139.1, 132.9, 131.1 (q, J C -F = 32.4 Hz), 130.0, 129.5 (q, J C -F = 31.7 Hz), 128.5, 125.4 (m ), 125.1, 124.1 (q, J C -F = 270.8 Hz), 123.2 (q, J C -F = 270.8 Hz), 124.1, 122.7, 121.6, 121.3 (m), 120.5 (m), 120.1, 118.4, 116.6 (m). HRMS m / z calcd for C ₂₄ H ₁₃ F ₃ N ₄ O ₂ 560.0895; found 560.0894.

Example  1-9: 5- (4- (3,5- Difluorophenyl )-One H -1,2,3- Triazole Yl) -2- Hydroxy - N - (3- ( Trifluoromethyl ) Phenyl ) Benzamide  (3b)

Following the general method for the general formula (3), 1: Compound 7h (96.7 mg, 300 μmol) in _{1 t -BuOH / H 2 O (} 3 mL), benzene (55 a-3, 5-difluoro-1-ethynyl _{μL, 450 μmol), CuSO 4} (4.8 mg, 30 μmol) and Na. ascorbate (29.7 mg, 150 μmol). The reaction mixture was stirred at room temperature for 3.25 h. Then, additional CuSO ₄ (9.6 mg, 60.0 μmol) and 1-ethynyl-3,5-difluorobenzene (18.0 μL, 150 μmol) were added and stirred at room temperature for 45 hours. Column chromatography (4: 1 hexane / EtOAc) provided compound 3b as a light yellow solid (64.6 mg, 47%).

_{TLC: R f 0.10 (6:} 1 hexane / EtOAc). ^{Mp: 345-347 o C. 1 H-} NMR (400 MHz, DMSO- d 6): δ 11.76 (s, 1H), 10.80 (s, 1H), 9.38 (s, 1H), 8.33 (d, J = 2.8 Hz, 1H), 8.23 ( s, 1H), 7.95-7.92 (m, 2H), 7.63 (dd, J H -F = 9.6 Hz, J H -H = 2.4 Hz, 2H), 7.61 (t, J = 8.0 Hz, 1H), 7.48 (d, J = 8.0 Hz, 1H), 7.25 (tt, J H -F = 9.6 Hz, J H -H = 2.4 Hz, 1H), 7.22 (d, J = 8.8 Hz , 1H). ^{13 C-NMR (100 MHz,} DMSO- d 6): δ 165.0, 162.9 (dd, J C -F = 244.7, 13.9 Hz), 157.5 , 145.2, 139.1, 133.8, 130.1, 129.5 (q, J C -F = 31.5 Hz), 128.5, 125.3, 124.1, 124.0 (q, J _{C -F} = 270 Hz), 121.5, 121.2 , 120.5 (m), 120.1, 118.4, 116.6 (m), 108.2 (d, J C -F = 26.4 Hz), 103.4 (t, J _CF = 26.4 Hz). _{HRMS m / z calcd for C 22} H 13 F 5 N 4 O 2 460.0959; found 460.0957.

Example  1-10: 5- (4- (4- (dimethylamino) Phenyl -One H -1,2,3- Triazole Yl) -2- Hydroxy - N - (3- ( Trifluoromethyl ) Phenyl ) Benzamide  (3c)

Following the general method for the general formula (3), 1: Compound in _{1 t -BuOH / H 2 O (} 3 mL) 7h (96.7 mg, 300 μmol), ethynyl-4- - N, N - dimethyl aniline (112 μL, _{750 μmol), CuSO 4 (9.6} mg, 60 μmol) and Na. ascorbate (59.4 mg, 300 [mu] mol). The reaction mixture was stirred at room temperature for 20 hours. Compound 3c was obtained in the form of a dark brown solid (80.0 mg, 57%) using column chromatography (2: 1 hexane / EtOAc to 20: 1 CH ₂ Cl ₂ / MeOH).

_{TLC: R f 0.24 (2:} 1 hexane / EtOAc). ^{Mp: 223.5-225.5 o C. 1 H-} NMR (400 MHz, DMSO- d 6): δ 11.73 (br s, 1H), 10.90 (br s, 1H), 9.02 (s, 1H), 8.36 (d, J = 2.8 Hz, 1H), 8.25 (s, 1H), 7.98-7.95 (m, 2H), 7.75 (d, J = 8.8 Hz, 2H), 7.64 (t, J = 8.0 Hz, 1H), 7.50 ( (d, J = 8.0 Hz, 1H), 7.20 (d, J = 8.8 Hz, 1H), 6.82 (d, J = 8.8 Hz, 2H), 2.95 (s, 6H). ^{13 C-NMR (100 MHz,} DMSO- d 6): δ 165.4, 157.7, 150.2, 147.8, 139.1, 130.0, 129.3 (q, J C -F = 31.5 Hz), 128.7, 126.2 , 125.2, 124.2, 124.1 (q, J C -F = 270 Hz), 121.1, 120.4 (m), 119.6, 118.4, 118.0, 117.6, 116.6 (m), 112.3, 53.6. HRMS m / z calcd for C ₂₄ H ₂₀ F ₃ N ₅ O ₂ 467.1569; found 467.1569.

Example  1-11: 5- (4- (4- Cyanophenyl )-One H -1,2,3- Triazole -1-yl) -2-hydroxy- N - (3- ( Trifluoromethyl ) Phenyl ) Benzamide  (3d)

(96.7 mg, 300 μmol), 4-ethynylbenzonitrile (98.3 mg, 750 μmol) in 1: 1 t- BuOH / H ₂ O (3 mL) CuSO ₄ (9.6 mg, 60 μmol) and Na. ascorbate (59.4 mg, 300 μmol) was used. The reaction mixture was stirred at 80 < 0 > C for 2 hours. Column chromatography (3: 1 hexane / EtOAc) provided compound 3d as a yellow solid (42.0 mg, 31%).

_{TLC: R f 0.40 (4:} 1 hexane / EtOAc). ^{Mp: 244-246 o C. 1 H-} NMR (400 MHz, DMSO- d 6): δ 11.79 (br s, 1H), 11.96 (br s, 1H), 9.42 (s, 1H), 8.34 (d, J = 2.8 Hz, 1H), 8.26 (s, 1H), 8.14 (d, J = 8.4 Hz, 2H), 7.98 (d, J = 8.4 Hz, 2H), 7.94-7.89 (m, 2H), 7.62 ( t, J = 7.6 Hz, 1H), 7.47 (d, J = 7.6 Hz, 1H), 7.13 (m, 1H). ^{13 C-NMR (100 MHz,} DMSO- d 6): δ 165.1, 157.6, 145.6, 139.1, 134.8, 133.1, 130.0, 129.5 (q, J C -F = 31.7 Hz), 128.5, 125.8, 125.4, 124.1, 124.0 (q, J _{C -F} = 270 Hz), 121.5, 121.4, 120.5 (m), 120.0, 118.7, 118.4, 116.6 (m), 110.4. HRMS m / z calcd for C ₂₃ H ₁₄ F ₃ N ₅ O ₂ 449.1100; found 449.1100.

Example  1-12: 5- (4- (5- Chloro -2,4- Dimethoxyphenyl )-One H -1,2,3- Triazole Yl) -2- Hydroxy - N - (3- ( Trifluoromethyl ) Phenyl ) Benzamide  (3e)

According to the general preparation method for the above formula 3, 1: 1 t -BuOH / H 2 O (2 mL) -2,4- compound 7h ethynyl (63.7 mg, 200 μmol) and 1-chloro-5-dimethoxy in ethoxy-benzene (106 mg, 500 μmol), CuSO 4 (6.4 mg, 40 μmol) and Na. ascorbate (39.6 mg, 200 μmol) was used. The reaction mixtures were stirred at room temperature for 3 hours and at 60 ^° C for 16.5 hours. Compound 3e was obtained as a brown solid (48.6 mg, 47%) using column chromatography (5: 1 to 1: 1 hexane / EtOAc).

_{TLC: R f 0.41 (20:} 1 CH 2 Cl 2 / MeOH). ^{Mp: 266.5-268.5 o C. 1 H-} NMR (400 MHz, DMSO- d 6): δ 11.75 (. Br s 1H), 10.79 (br s, 1H), 8.86 (s, 1H), 8.39 (d, J = 2.8 Hz, 1H), 8.25 (s, 1H), 8.13 (s, 1H), 8.01 (dd, J = 8.8, 2.8 Hz, 1H), 7.98 (d, J = 8.0 Hz, 1H), 7.64 ( t, J = 8.0 Hz, 1H ), 7.51 (d, J = 8.0 Hz, 1H), 7.11 (d, J = 8.8 Hz, 1H), 6.93 (s, 1H), 4.03 (s, 3H), 3.96 ( s, 3H). ^{13 C-NMR (100 MHz,} DMSO- d 6): δ 165.6, 157.6, 155.6, 155.1, 141.8, 139.0, 130.0, 129.5 (q, J C -F = 31.5 Hz), 128.7, 126.9, 125.8, 124.3, _{124.1 (q, J C -F =} 271.0 Hz), 121.4, 121.1, 120.5, 119.4, 118.2, 116.8 (q, J C -F = 3.6 Hz), 112.5, 111.9, 97.8, 56.4, 56.2. _{HRMS m / z calcd for C 24} H 12c lF 3 N 4 O 4 518.0969; found 518.0970.

Example  1-13: 5- (4- (3- Chlorophenyl )-One H -1,2,3- Triazole -1-yl) -2-hydroxy- N - (3- ( Trifluoromethyl ) Phenyl ) Benzamide  (3f)

(48.3 mg, 150 μmol), 1-chloro-3-ethynylbenzene (46.2 μL, 375 mg) was added in a 1: 1 t- BuOH / H ₂ O , CuSO ₄ (5.0 mg, 30.0 μmol) and Na. ascorbate (30.0 mg, 150 μmol). The reaction mixture was stirred at room temperature for 3 hours and at 60 ^° C for 1 hour. Compound 3f was obtained as a brown solid (49.0 mg, 71%) using column chromatography (6: 1 hexane / EtOAc to 30: 1 CH ₂ Cl ₂ / MeOH).

_{TLC: R f 0.41 (20:} 1 CH 2 Cl 2 / MeOH). ^{Mp: 260-262 o C. 1 H-} NMR (400 MHz, DMSO- d 6): δ 11.76 (. Br s 1H), 10.76 (br s, 1H), 9.36 (s, 1H), 8.38 (d, J = 2.8 Hz, 1H), 8.25 (s, 1H), 8.01-7.97 (m, 3H) 7.93 (dt, J = 1.2, 7.6 Hz, 1H), 7.64 (t, J = 7.6 Hz, 1H), 7.55 (d, J = 7.6 Hz, 1H), 7.51 (d, J = 7.6 Hz, 1H), 7.45 (ddd, J = 7.6, 2.4, 1.2 Hz, 1H), 7.24 (d, J = 8.8 Hz, 1H) . ^{13 C-NMR (100 MHz,} DMSO- d 6): δ 165.2, 157.3, 144.8, 139.1, 133.8, 132.4, 130.1, 130.0, 129.5 (q, J C -F = 31.3 Hz), 128.7, 128.0, 125.3, 124.9, 124.2, 124.1 (q, J C -F = 270.0 Hz), 123.8, 121.4, 120.5, 120.0, 119.5, 118.3, 116.6. _{HRMS m / z calcd for C 22} H 14 ClF 3 N 4 O 2 458.0757; found 458.0757.

Example  1-14: methyl  4- (1- (4- Hydroxy -3 - ((3- ( Trifluoromethyl ) Phenyl ) Carbamoyl ) Phenyl -One H -1,2,3- Triazole Yl) Benzoate  (3 g)

Following the general method for the general formula 3, 1: 1 t -BuOH / H 2 O in the compound (4 mL) 7h (128 mg , 400 μmol), ethynyl benzoic acid methyl ester 4- (161 mg, 1.00 mmol) , CuSO ₄ (12.8 mg, 80.2 μmol) and Na. ascorbate (78.2 mg, 395 μmol) was dissolved. The reaction mixture was stirred at room temperature for 5 hours and at 40 ^° C for 59 hours. 3 g of the compound were obtained as a brown solid (90.0 mg, 47%) using column chromatography (5: 1 hexane / EtOAc to 20: 1 CH ₂ Cl ₂ / MeOH).

_{TLC: R f 0.57 (20:} 1 CH 2 Cl 2 / MeOH). ^{Mp: 258-260 o C. 1 H-} NMR (400 MHz, DMSO- d 6): δ 11.79 (br s 1H.), 9.41 (d, J = 2.4 Hz, 1H), 8.38 (s, 1H), (D, AB system, J = 8.8 Hz, 2H), 8.09 (d, AB system, J = 8.8 Hz, 2H), 7.97-7.95 (m, 2H), 7.63 J = 7.6 Hz, 1H), 7.49 (d, J = 7.6 Hz, 1H), 7.18 (m, 1H), 3.89 (s, 3H). ^{13 C-NMR (100 MHz,} DMSO- d 6): δ 166.0, 165.3, 157.6, 146.2, 139.1, 134.8, 130.1, 130.0, 129.6 (q, J C -F = 31.5 Hz), 129.0, 128.6, 125.4, _{124.2, 124.1 (q, J C} -F = 263.7 Hz), 121.5, 121.0, 120.5 (m), 119.9, 118.4, 117.6, 116.7 (m), 52.2. HRMS m / z calcd for C ₂₄ H ₁₇ F ₃ N ₄ O ₄ 482.1202; found 482.1206.

Example  1-15: 2- Hydroxy -5- (4- ( m - tolyl) -1 H -1,2,3- Triazole -1 day)- N - (3- (trifluoromethyl) Phenyl ) Benzamide  (3h)

Following the general method for the general formula 3, 1: 1 t -BuOH / H 2 O (1.5 mL) to compound 7h (47.7 mg, 150 μmol) , m - tolyl acetylene (48.4 μL, 375 μmol), CuSO 4 (4.8 mg, 30 μmol) and Na. ascorbate (30.0 mg, 150 μmol) was dissolved. The reaction mixture was stirred for 1.5 hours at 40 ^o C. Compound 3h was obtained as a brown solid (56.8 mg, 86%) using column chromatography (5: 1 hexane / EtOAc to 20: 1 CH ₂ Cl ₂ / MeOH)

_{TLC: R f 0.35 (20:} 1 CH 2 Cl 2 / MeOH). ^{Mp: 235.5-237.5 o C. 1 H-} NMR (400 MHz, DMSO- d 6): δ 11.75 (. Br s 1H), 10.85 (br s, 1H), 9.24 (s, 1H), 8.39 (d, J = 2.8 Hz, 1H), 8.25 (s, 1H), 8.00-7.97 (m, 2H), 7.79 (s, 1H), 7.74 (d, J = 8.0 Hz, 1H), 7.64 (t, J = 8.0 8.0 Hz, 1H), 7.50 (d, J = 8.0 Hz, 1H), 7.38 (t, J = 8.0 Hz, 1H), 7.23-7.19 (m, 2H), 2.39 (s, ^{13 C-NMR (100 MHz,} DMSO- d 6): δ 165.3, 157.4, 147.3, 139.1, 138.1, 130.2, 130.0, 129.5 (q, J C -F = 31.5 Hz), 128.9, 128.8, 128.7, 125.8, 125.3, 124.4 (q, J = _{C- F} = 270.0 Hz), 124.2, 122.5, 121.2, 120.5, 119.8, 119.6, 118.3, 116.7, 21.1. HRMS m / z calcd for C ₂₃ H ₁₇ F ₃ N ₄ O ₂ 438.1304; found 438.1310.

Example  1-16: 2- Hydroxy -5- (4- ( p - tolyl) -1 H -1,2,3- Triazole -1 day)- N - (3- (trifluoromethyl) Phenyl ) Benzamide  (3i)

(47.9 mg, 150 μmol), p -tolylacetylene (47.6 μL, 375 μmol), CuSO ₄ (4.8 g, 150 μmol) were added to a 1: 1 t- BuOH / H ₂ O mg, 30 μmol) and Na. ascorbate (30.0 mg, 150 μmol) was dissolved. The reaction mixture was stirred for 1.5 hours at 40 ^o C. Compound 3i was obtained as a brown solid (39.8 mg, 61%) using column chromatography (5: 1 hexane / EtOAc to 20: 1 CH ₂ Cl ₂ / MeOH).

_{TLC: R f 0.33 (20:} 1 CH 2 Cl 2 / MeOH). ^{Mp: 457-459 o C. 1 H-} NMR (400 MHz, DMSO- d 6): δ 11.76 (. Br s 1H), 11.01 (br s, 1H), 9.19 (s, 1H), 8.38 (d, J = 2.4 Hz, 1H), 8.25 (s, 1H), 7.98-7.96 (m, 2H), 7.84 (d, J = 8.0 Hz, 2H), 7.63 (t, J = 8.0 Hz, 1H), 7.50 ( (d, J = 8.0 Hz, 1H), 7.31 (d, J = 8.0 Hz, 2H), 7.19 (d, J = 8.8 Hz, ^{13 C-NMR (100 MHz,} DMSO- d 6): δ 165.4, 157.9, 147.4, 139.2, 137.7, 130.1, 129.6, 129.5 (q, J C -F = 31.5 Hz), 128.7, 127.6, 125.4, 125.3, _{124.3, 124.2 (q, J C} -F = 270.0 Hz), 121.4, 120.5, 119.7, 119.3, 118.5, 116.7, 20.9. HRMS m / z calcd for C ₂₃ H ₁₇ F ₃ N ₄ O ₂ 438.1304; found 438.1312.

Example  1-17: 5- (4- (4- Fluorophenyl )-One H -1,2,3- Triazole Yl) -2- Hydroxy - N - (3- ( Trifluoromethyl ) Phenyl ) Benzamide  (3j)

Following the general method for the general formula 3, 1: 1 t -BuOH / H 2 O (1.5 mL) to compound 7h (48.0 mg, 150 μmol) , 4- fluoro-phenyl acetylene (49.0 μL, 375 μmol), CuSO 4 (4.8 mg, 30 [mu] mol) and Na. ascorbate (30.0 mg, 150 μmol) was dissolved. The reaction mixture was stirred for 1.5 hours at 40 ^° C. Compound 3j was obtained as a brown solid (61.4 mg, 97%) using column chromatography (5: 1 hexane / EtOAc to 20: 1 CH ₂ Cl ₂ / MeOH).

_{TLC: R f 0.35 (20:} 1 CH 2 Cl 2 / MeOH). ^{Mp: 255-257 o C. 1 H-} NMR (400 MHz, DMSO- d 6): δ 11.76 (. Br s 1H), 10.95 (br s, 1H), 9.24 (s, 1H), 8.37 (d, J = 2.8 Hz, 1H), 8.25 (s, 1H), 8.00-7.95 (m, 4H), 7.63 (t, J = 8.0 Hz, 1H), 7.50 (d, J = 8.0 Hz, 1H), 7.35 ( t, J = 8.8 Hz, 2H), 7.20 (d, J = 8.8 Hz, 1H). ^{13 C-NMR (100 MHz,} DMSO- d 6): δ 165.2, 162.0 (d, J C -F = 253.2 Hz), 157.4, 146.3, 139.1, 130.0, 129.5 (q, J C -F = 31.7 Hz) , 128.7, 127.4 (q, J C -F = 8.1 Hz), 126.9, 125.3, 124.2, 124.1 (q, J C -F = 270.0 Hz), 121.4, 120.5, 119.9, 119.7, 118.3, 116.6, 115.9 (d , J _{C -F} = 21.2 Hz). _{HRMS m / z calcd for C 22} H 14 F 4 N 4 O 2 442.1053; found 442.1051.

Example  1-18: 2- Hydroxy -5- (4- (pyridin-3-yl) -1H-1,2,3- Triazole -1-yl) -N- (3- ( Trifluoromethyl ) Phenyl ) Benzamide  (3k)

As a general production method of the formula 3, 1: 1 t -BuOH / H 2 O (1.5 mL) to compound 7h (48.3 mg, 150 μmol) ,, CuSO 4 pyridine (15.5 mg, 150 μmol) 3-ethynyl (4.8 mg, 30 [mu] mol) and Na. ascorbate (30.0 mg, 150 μmol) was dissolved. The reaction mixture was stirred at room temperature for 22 hours. Additional CuSO ₄ (10.0 mg, 60.0 μmol) was added and stirred at 80 ^° C for 22 h. Compound 3k was obtained as a brown solid (50.0 mg, 78%) using column chromatography (30: 1 CH ₂ Cl ₂ / MeOH).

_{TLC: R f 0.29 (20:} 1 CH 2 Cl 2 / MeOH). ^{Mp: 238.5-240.5 o C. 1 H-} NMR (400 MHz, DMSO- d 6): δ 10.90 (br s, 2H), 9.36 (s, 1H), 9.19 (br s, 1H), 8.61 (br s J = 8.0 Hz, 1H), 8.25 (s, 1H), 7.97-7.95 (m, 2H), 7.63 (t, J = 8.0 Hz, 1H), 8.37 , 7.56 (br s, 1 H), 7.50 (d, J = 8.0 Hz, 1 H), 7.23 (d, J = 8.8 Hz, 1 H). ^{13 C-NMR (100 MHz,} DMSO- d 6): δ 165.1, 163.4, 157.5, 149.1, 146.5, 144.5, 139.1, 132.4, 130.0, 129.3 (q, J C -F = 31.5 Hz), 128.6, 125.4, 125.3, 124.1, 124.0 (q, J CF = 269.4 Hz), 121.5, 120.5, 120.4, 120.0, 118.4, 116.6 (q, J C -F = 3.7 Hz). _{HRMS m / z calcd for C 21} H 14 F 3 N 5 O 2 425.1100; found 426.1104.

Example  1-19: 2- Hydroxy -5- (4- (thiophen-3-yl) -1 H -1,2,3- Triazole -1 day)- N - (3- ( Trifluoromethyl ) Phenyl ) Benzamide  (3l)

Following the general method for the general formula 3, 1: 1 t -BuOH / H 2 O (1.5 mL) to compound 7h (48.3 mg, 150 μmol) , 3- ethynyl nilti thiophene (37.0 μL, 375 μmol), CuSO 4 ( 4.8 mg, 30 [mu] mol) and Na. ascorbate (30.0 mg, 150 μmol) was dissolved. The reaction mixture was stirred at room temperature for 22 hours. 3l of the compound was obtained in the form of a brown solid (53.7 mg, 83%) using column chromatography (30: 1 - > 10: 1 CH ₂ Cl ₂ / MeOH).

_{TLC: R f 0.61 (20:} 1 CH 2 Cl 2 / MeOH). ^{Mp: 275-277 o C. 1 H-} NMR (400 MHz, DMSO- d 6): δ 11.75 (. Br s 1H), 10.88 (br s, 1H), 9.11 (s, 1H), 8.36 (d, J = 2.8 Hz, 1H), 8.25 (s, 1H), 7.98-7.95 (m, 2H), 7.94 (dd, J = 3.2, 1.2 Hz, 1H), 7.70 (dd, J = 4.8, 1.2 Hz, 1H ), 7.64 (t, J = 7.6 Hz, 1H), 7.59 (dd, J = 4.8, 1.2 Hz, 1H), 7.50 (d, J = 7.6 Hz, 1H), 7.21 (d, J = 8.8 Hz, 1H ). ^{13 C-NMR (100 MHz,} DMSO- d 6): δ 165.3, 157.4, 143.8, 139.1, 131.6, 130.1, 129.5 (q, J C -F = 31.3 Hz), 128.7, 127.4, 125.8, 125.3, 124.2, _{124.1 (q, J C -F =} 274 Hz), 121.4, 121.3, 120.5 (m), 119.8, 119.5, 118.4, 116.7 (m). _{HRMS m / z calcd for C 20} H 13 F 3 N 4 O 2 S 430.0711; found 430.0709.

Example  1-20: 5- (4- (3- Acetamidophenyl )-One H -1,2,3- Triazole Yl) -2- Hydroxy - N - (3- ( Trifluoromethyl ) Phenyl ) Benzamide  (3 m)

(48.3 mg, 150 μmol) and N - (3-ethynylphenyl) acetamide (59.7 mg, 0.1 mmol) were added to 1: 1 t- BuOH / H ₂ O (1.5 mL) 375 μmol), CuSO ₄ (4.8 mg, 30 μmol) and Na. ascorbate (30.0 mg, 150 μmol) was dissolved. The reaction mixture was stirred at room temperature for 19 hours. Additional CuSO ₄ (4.8 mg, 30 μmol) was added and stirred at 80 ^° C for 20 h. Column chromatography (30: 1 CH ₂ Cl ₂ / MeOH) provided 3 m of the compound as a brown solid (61.7 mg, 85%).

_{TLC: R f 0.16 (30:} 1 CH 2 Cl 2 / MeOH). ^{Mp: 258-260 o C. 1 H-} NMR (400 MHz, DMSO- d 6): δ 10.89 (. Br s 1H), 10.08 (br s, 1H), 9.19 (s, 1H), 8.40 (d, J = 2.4 Hz, 1H), 8.26-8.24 (m, 2H), 7.99 (dd, J = 8.8, 2.4 Hz, 1H), 7.97 (d, J = 8.0 Hz, 1H), 7.64 (t, J = 8.0 Hz, 1H), 7.59-7.55 (m , 2H), 7.50 (d, J = 8.0 Hz, 1H), 7.40 (t, J = 8.0 Hz, 1H), 7.21 (d, J = 8.8 Hz, 1H), 2.07 (s, 3 H). ^{13 C-NMR (100 MHz,} DMSO- d 6): δ 168.5, 165.5, 157.7, 147.2, 139.9, 139.1, 130.8, 130.1, 129.5 (q, J C -F = 31.3 Hz), 129.4, 128.7, 125.5, _{124.4 (q, J C -F =} 270.0 Hz), 124.3, 121.4, 120.5 (q, J C -F = 3.7 Hz), 120.4, 119.7, 119.6, 118.9, 118.4, 116.7 (q, J C -F = 3.7 Hz), 115.9, 24.1. _{HRMS m / z calcd for C 24} H 12f3 N 5 O 3 481.1362; found 481.1359.

Example  1-21: methyl  3- (1- (4- Hydroxy -3 - ((3- ( Trifluoromethyl ) Phenyl ) Carbamoyl ) Phenyl )-One H -1,2,3- Triazole Yl) Benzoate  (3n)

(112 mg, 350 [mu] mol), 3-ethynylbenzoic acid methyl ester (62.0 mg, 380 [mu] mol), and _2- bromoaniline were added to 1: 1 t- BuOH / H2O CuSO ₄ (22.3 mg, 140 μmol) and Na. ascorbate (69.0 mg, 350 μmol) was dissolved. The mixture was stirred at room temperature for 2 hours and at 80 ^° C for 44 hours. Compound 3n was obtained in the form of a brown solid (145 mg, 86%) using column chromatography (4: 1 hexane / EtOAc to 30: 1 CH ₂ Cl ₂ / MeOH).

_{TLC: R f 0.10 (5:} 1 hexane / EtOAc). ^{Mp: 214-216 o C. 1 H-} NMR (400 MHz, DMSO- d 6): δ 10.85 (br s 1H.), 9.41 (s, 1H), 8.54 (t, J = 1.2 Hz, 1H), 8.40 (d, J = 2.8 Hz , 1H), 8.25 (s, 1H), 8.23 (dt, J = 8.0, 1.2 Hz, 1H), 8.00 (dd, J = 8.8, 2.8 Hz, 1H), 7.98-7.96 (m, 2H), 7.67 ( t, J = 7.6 Hz, 1H), 7.64 (t, J = 8.0 Hz, 1H), 7.51 (d, J = 7.6 Hz, 1H), 7.22 (d, J = 8.8 Hz , ≪ / RTI > 1H), 3.91 (s, 3H). ^{13 C-NMR (100 MHz,} DMSO- d 6): δ 166.1, 165.3, 157.5, 146.3, 139.1, 130.9, 130.5, 130.1, 129.9, 129.7, 129.4 (q, J C -F = 31.5 Hz), 128.8, 128.7, 125.8, 125.4, 124.3, 124.2 (q, J C -F = 270.0 Hz), 121.4, 120.6 (m), 120.3, 119.9, 118.4, 116.8 (m), 52.4. HRMS m / z calcd for C ₂₄ H ₁₇ F ₃ N ₄ O ₄ 482.1202; found 482.1200.

Example  1-22: 2- Hydroxy -5- (4- (pyridin-2-yl) -1 H -1,2,3- Triazole -1 day)- N - (3- ( Trifluoromethyl ) Phenyl ) Benzamide  (3o)

As a general production method of the formula 3, 1: 1 t -BuOH / H 2 O (1 mL) compound 7h (35.4 mg, 110 μmol) in, pyridine (28.0 μL, 280 μmol) ethynyl, 2-, ₄ CuSO (7.0 mg, 44.0 [mu] mol) and Na. ascorbate (21.8 mg, 110 μmol) was dissolved. The mixture was stirred at room temperature for 1 hour and at 60 ^° C for 42 hours. After the reaction was complete, pyridine (0.1 mL) was added to the crude mixture to improve low solubility. Compound 3o was obtained as a brown solid (12.5 mg, 27%) using column chromatography (30: 1 CH ₂ Cl ₂ / MeOH).

_{TLC: R f 0.43 (30:} 1 CH 2 Cl 2 / MeOH). ^{Mp: 274.5-276.5 o C. 1 H-} NMR (400 MHz, Acetone- d 6): δ 8.93 (s, 1H), 8.65 (d, J = 4.0 Hz, 1H), 8.59 (d, J = 2.8 Hz , 1H), 8.26 (s, 1H), 8.20 (d, J = 7.6 Hz, 1H), 8.14 (dd, J = 8.8, 2.8 Hz, 1H), 8.07 (d, J = 8.0 Hz, 1H), 7.93 (td, J = 7.6, 1.6 Hz, 1H), 7.67 (t, J = 8.0 Hz, 1H), 7.55 (d, J = 8.0 Hz, 1H), 7.37 (ddd, J = 7.6, 4.0, 1.2 Hz, 1H), 7.26 (d, J = 8.8 Hz, 1H). ^{13 C-NMR (100 MHz,} DMSO- d 6): δ 165.8, 158.3, 149.8, 149.6, 148.3, 139.1, 137.6, 130.3, 129.7 (q, J C -F = 31.5 Hz), 128.6, 128.3, 125.8, _{124.6, 124.2 (q, J C} -F = 270.0 Hz), 123.6, 121.4, 120.8, 120.0, 119.2, 118.6, 117.7 (q, J C -F = 3.7 Hz). _{HRMS m / z calcd for C 21} H 14 F 3 N 5 O 2 425.1100; found 425.1106.

Example  1-23: 2- Hydroxy -5- (4- (1- methyl -One H - Imidazole -5-yl) -1 H -1,2,3- Triazole -1 day)- N - (3- ( Trifluoromethyl ) Phenyl ) Benzamide  (3p)

(48.3 mg, 150 μmol), 5-ethynyl-1-methyl-1 H -imidazole (1.5 mmol) were added to 1: 1 t- BuOH / H ₂ O (40.0 μL, 380 μmol), CuSO ₄ (9.6 mg, 60.0 μmol) and Na. ascorbate (29.7 mg, 150 μmol) was dissolved. The mixture was stirred at room temperature for 2.5 hours and at 60 ^° C for 23 hours. After the reaction was complete, pyridine (0.1 mL) was added to the crude mixture to improve low solubility. Compound 3p was obtained as a white solid (34.8 mg, 54%) using column chromatography (40: 1 to 10: 1 CH ₂ Cl ₂ / MeOH).

_{TLC: R f 0.11 (20:} 1 CH 2 Cl 2 / MeOH). ^{Mp: 259-261 o C. 1 H-} NMR (400 MHz, DMSO- d 6): δ 10.90 (br s 1H.), 9.04 (s, 1H), 8.37 (d, J = 2.8 Hz, 1H), 8.24 (s, 1H), 7.97 (dd, J = 8.8, 2.8 Hz, 1H), 7.96 (d, J = 8.0 Hz, 1H), 7.78 (s, 1H), 7.63 (t, J = 8.0 Hz, 1H ), 7.50 (d, J = 8.0 Hz, IH), 7.32 (s, IH), 7.21 (d, J = 8.8 Hz, IH), 3.88 (s, 3H). ^{13 C-NMR (100 MHz,} DMSO- d 6): δ 165.4, 157.9, 139.2, 138.3, 131.7, 130.1, 129.5 (q, J C -F = 31.4 Hz), 128.7, 128.4, 125.5, 124.2, 124.1 ( _{q, J CF = 270.0 Hz)} , 122.8, 121.6, 120.5, 120.1, 119.9, 118.5, 116.7 (q, J C -F = 3.7 Hz), 33.1. _{HRMS m / z calcd for C 20} H 15 F 3 N 6 O 2 428.1209; found 428.1215.

Example  2: General Preparation Method for the Synthesis of Compounds of Formulas 2h, 3q and 3r [ Hydrolysis reaction ]

A suspension of methyl ester (100 [mu] mol) in NaOH (1 mL) and MeOH (1 mL) ^o C < / RTI > After the reaction was complete, the methanol was evaporated. The residue was acidified with 1 N HCl (pH 5) and extracted with EtOAc (3 x 10 mL). The combined organic extracts were dried using anhydrous MgSO ₄ , filtered and concentrated by rotary evaporation to produce the carboxylic acid.

Example  2-1: 3- (5- (4- (3,5- Dimethoxyphenyl )-One H -1,2,3- Triazole Yl) -2- Hydroxybenzamide ) Benzoic acid (2h)

2 g (33.6 mg, 70.0 μmol) of the methyl ester compound was dissolved in NaOH (0.7 mL) and MeOH (0.7 mL) to give compound 2h as a light brown solid (22.4 mg , 70%).

_{TLC: R f 0.16 (30:} 1 CH 2 Cl 2 / MeOH). ^{Mp: 235-237 o C. 1 H-} NMR (400 MHz, DMSO- d 6): δ 11.99 (br s, 1H), 10.66 (br s, 1H), 9.26 (s, 1H), 8.41 (d, J = 2.4 Hz, 1H), 8.38 (t, J = 1.6 Hz, 1H), 7.99-7.96 (m, 1H), 7.73 (dt, J = 1.2, 7.6 Hz, 1H), 7.52 (t, J = 7.6 Hz, 1H), 7.26-7.13 (m, 2H), 7.13 (d, J = 2.4 Hz, 2H), 6.51 (t, J = 2.4 Hz, 1H), 3.82 (s, 6H). ^{13 C-NMR (100 MHz,} DMSO- d 6): δ 167.1, 165.3, 161.0, 157.7, 147.2, 138.5, 132.2, 129.2, 128.9, 128.3, 125.4, 125.1, 124.9, 121.4, 121.3, 120.2, 119.6, 118.4 , 103.3, 100.3, 55.4. HRMS m / z calcd for C ₂₄ H ₂₀ N ₄ O ₆ 460.1383; found 460.1386.

Example  2-2: 4- (1- (4- Hydroxy -3 - ((3- ( Trifluoromethyl ) Phenyl ) Carbamoyl ) Phenyl-1 H -1,2,3- Triazole -4-yl) benzoic acid (3q)

According to the general procedure described above, 3 g (48.2 mg, 100 μmol) of the methyl ester compound were dissolved in NaOH (1 mL) and MeOH (1 mL) to give 3q as a light brown solid (44.6 mg, 96 %).

_{TLC: R f 0.10 (1:} 1 hexane / EtOAc). ^{Mp: 309.5-311.5 o C. 1 H-} NMR (400 MHz, DMSO- d 6): δ 13.02 (br s, 1H), 11.77 (br s, 1H), 10.77 (. Br s 1H), 9.41 (s J = 8.8, 2.8 Hz, 1H), 7.97 (d, 1H), 8.40 (d, J = 2.8 Hz, 1H) J = 8.0 Hz, 1H), 7.64 (t, J = 8.0 Hz, 1H), 7.51 (d, J = 8.0 Hz, 1H), 7.24 (d, J = 8.8 Hz, 1H). ^{13 C-NMR (100 MHz,} DMSO- d 6): δ 167.0, 165.2, 157.4, 146.3, 139.1, 134.4, 130.2, 130.1, 130.0, 129.5 (d, J C -F = 31.3 Hz), 128.7, 125.4, 125.3, 124.2, 124.1 (d, J C -F = 270.0 Hz), 121.4, 120.8, 120.5, 119.9, 118.3, 116.7. HRMS m / z calcd for C ₂₃ H ₁₅ F ₃ N ₄ O ₄ 468.1045; found 468.1042.

Example  2-3: 3- (1- (4- Hydroxy -3 - ((3- ( Trifluoromethyl ) Phenyl ) Carbamoyl ) Phenyl) -1 H -1,2,3- Triazole -4-yl) benzoic acid (3r)

According to the general procedure described above, the methyl ester compound 3n (48.2 mg, 100 μmol) was dissolved in NaOH (1 mL) and MeOH (1 mL), from which compound 3r was obtained in the form of a brown solid (44.9 mg, 98% ).

_{TLC: R f 0.37 (20:} 1 CH 2 Cl 2 / MeOH). ^{Mp: 299-301 o C. 1 H-} NMR (400 MHz, DMSO- d 6): δ 11.76 (br s, 1H), 10.78 (. Br s 1H), 9.42 (s, 1H), 8.53 (t, J = 1.2 Hz, 1H), 8.42 (d, J = 2.8 Hz, 1H), 8.25 (s, 1H), 8.20 (dt, J = 1.2, 8.0 Hz, 1H), 8.02 (dd, J = 2.8, 8.8 Hz, 1H), 7.98 (d , J = 8.8 Hz, 1H), 7.95 (dt, J = 1.2, 8.0 Hz, 1H), 7.66-7.62 (m, 2H), 7.51 (d, J = 7.6 Hz, 1H ), 7.23 (d, J = 8.8 Hz, 1 H). ^{13 C-NMR (100 MHz,} DMSO- d 6): δ 167.1, 165.3, 157.5, 146.5, 139.1, 131.6, 130.7, 130.1, 129.7, 129.4, 129.3 (q, J C -F = 31.5 Hz), 128.9, 128.8, 126.0, 125.3, 124.2, 124.1 (q, J 2 _{C -F} = 268.5 Hz), 121.3, 120.5, 120.2, 119.9, 118.3, 116.7. HRMS m / z calcd for C ₂₃ H ₁₅ F ₃ N ₄ O ₄ 468.1045; found 468.1043.

Experimental Example : Biological Screening

In order to evaluate the Aurora kinase inhibitory activity of 1,2,3-triazolyl salicylamide derivatives according to the present invention, in-vitro kinase assays for Aurora A and B were performed. Kinase assay was performed at Reaction Biology Corporation using the 'HotSpot' assay platform.

The Kinase assay protocol is as follows:

Reaction buffer: base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl 2, 1 mM EGTA, 0.02% Brij35, 0.02 mg / mL BSA, 0.1 mM Na 3 VO 4, 2 mM DTT, 1% DMSO.

Reaction Process: The co-factor required for the enzymatic reaction was added to the freshly prepared buffer solution, and then 20 μM of the selected kinase was added. The contents were gently mixed and then the compound to be tested was dissolved in DMSO and added to the reaction mixture at a concentration of 10 [mu] M. For the determination of the specific IC ₅₀ of the compounds which are particularly active then the selected compounds were tested in a 10-dose IC ₅₀ mode by starting with 30 μM and triple serial dilutions. ³³ P-ATP (specific activity 0.01 μCi / lL) was added to the mixture to initiate the reaction, and the mixture was incubated at room temperature for 2 hours. As a positive control, a known nonselective kinase inhibitor, staurosporine, was used in a five-dose IC ₅₀ mode starting at 20 [mu] M and diluted 10-fold, and the reaction was performed at a concentration of 10 [mu] M ATP. The results are shown in Tables 1 and 2 below.

Table 1 below shows the% inhibition of kinase activity as a mean value of duplicate assays for the specific compounds according to the invention.

Inhibitory activity of 1,2,3-triazolyl salicylamide compounds 2 and 3 against Aur A and B compound R ¹ R ² Ar % inhibition ^b AurA AurB 2a H m -CF ₃ 3,5-dimethoxyphenyl 30.0 4.4 2b OH H 3,5-dimethoxyphenyl 88.8 65.9 2c OH m -CH ₃ 3,5-dimethoxyphenyl 4.2 11.8 2d OH m -OCH ₃ 3,5-dimethoxyphenyl 83.3 50.3 2e OH m- Cl 3,5-dimethoxyphenyl 91.8 56.3 2f OH o -CF ₃ 3,5-dimethoxyphenyl 22.4 21.3 2g OH m -CO ₂ CH ₃ 3,5-dimethoxyphenyl 90.2 71.3 2h OH m -CO ₂ H 3,5-dimethoxyphenyl 67.9 34.8 3a OH m -CF ₃ 3,5-bis (trifluoromethyl) phenyl 91.0 80.4 3b OH m -CF ₃ 3,5-difluorophenyl 88.9 39.5 3c OH m -CF ₃ p - (dimethylamino) phenyl 45.7 16.2 3d OH m -CF ₃ p- cyanophenyl 92.8 36.2 3e OH m -CF ₃ 5-chloro-2,4-dimethoxyphenyl 94.4 76.7 3f OH m -CF ₃ m -chlorophenyl 94.7 41.7 3g OH m -CF ₃ p - (methoxycarbonyl) phenyl 92.6 23.0 3h OH m -CF ₃ m- toluyl 92.5 30.6 3i OH m -CF ₃ p- toluyl 85.7 20.0 3j OH m -CF ₃ p- fluorophenyl 79.3 21.7 3k OH m -CF ₃ pyridin-3-yl 75.8 53.6 3l OH m -CF ₃ thiophen-3-yl 91.3 25.3 3m OH m -CF ₃ m- acetamidophenyl 92.5 71.4 3n OH m -CF ₃ m - (methoxycarbonyl) phenyl 90.5 57.3 3o OH m -CF ₃ pyridin-2-yl 78.0 44.9 3p OH m -CF ₃ 1-methyl-1 H -imidazol- 5-yl 46.4 42.3 3q OH m -CF ₃ p- Carboxyphenyl 63.5 27.4 3r OH m -CF ₃ m- Carboxyphenyl 52.5 39.6 Staurosporin IC ₅₀ (uM) - - - <0.001 0.001

a Enzyme assays were performed by Reaction Biology Corporation (http://www.reactionbiology.com).

b compounds were used at a concentration of 10 μM in the presence of 1 μM ATP. The test data represents the mean value of duplicated assays, and the percent inhibition was calculated by subtracting% enzyme activity from 100.

As can be seen from the above Table 1, eleven kinds of analogues (2e, 2g, 3a, 3d-h, 31-n) among the 26 kinds of 1,2,3-triazolyl salicylamides according to the present invention Aurora A showed more than 90% inhibitory effect, and other compounds showed relatively moderate mean inhibition. Interestingly, these 11 analogs showed a relatively high average inhibition rate (20.0% - 80.4% inhibition for Aurora B at 10 μM) for Aurora A than for Aurora B.

After this preliminary single-dose screening, the eleven species of salicylamides 2e, 2g, 3a, 3d to 3h, 3l to 3n exhibiting a 90% inhibition rate against Aurora A were selected for further testing. Among the above 11 compounds, nine compounds belonging to the formula (3) having a 3- (trifluoromethyl) phenyl moiety can be accommodated in the binding pocket of the aurora kinase. The IC ₅₀ values of the nine compounds were measured according to a 10-dose IC ₅₀ mode by three-fold serial dilutions starting at 30 μM. Most of the compounds exhibited IC ₅₀ values for nanoparticles ranging from nanomolar to low micromolar range of Aurora A. In particular, the formula 2g, 3a and 3e are shown an IC ₅₀ value in the nanomolar level. -CO ₂ CH ₃ with compound 2g group is a group represented by the IC ₅₀ value of 0.37 μM exhibited the best activity.

1,2,3-triazol jolil for AurA salicyl amide of the IC ₅₀ ^a compound structure IC ₅₀ (uM) ^b AurA AurB 2e

1.89 47.5 2g

0.37 3.58 3a

0.69 13.8 3d

1.44 ND ^c 3e

0.72 31.9 3f

1.56 ND ^c 3g

1.50 ND ^c 3h

3.83 ND ^c 3l

1.88 ND ^c 3m

4.16 21.8 3n

1.82 63.2 Staurosporine 0.001 0.006

^a Enzyme assays were performed by Reaction Biology Corporation (http://www.reactionbiology.com).

^b IC ₅₀ values were determined in the presence of 10 μM ATP.

^c Not determined.

Claims (11)

Aurora kinase A inhibitory activity,
A compound selected from the group consisting of the following compounds:
(1) Synthesis of N- (3-chlorophenyl) -5- (4- (3,5-dimethoxyphenyl) -1H-1,2,3- triazol- 1 -yl) -2-hydroxybenzamide 2e);
(2) Synthesis of methyl 3- (5- (4- (3,5-dimethoxyphenyl) -1H-1,2,3-triazol-1-yl) -2-hydroxybenzamido) benzoate );
(3) Synthesis of 5- (4- (3,5-bis (trifluoromethyl) phenyl) -1H-1,2,3- triazol- 1 -yl) -2- Trifluoromethyl) phenyl) benzamide (3a);
(4) Synthesis of 5- (4- (4-cyanophenyl) -1H-1,2,3-triazol-1-yl) -2- Benzamide (3d);
(5) Synthesis of 5- (4- (5-chloro-2,4-dimethoxyphenyl) -1H-1,2,3- triazol- Fluoromethyl) phenyl) benzamide (3e);
(6) Synthesis of 5- (4- (3-chlorophenyl) -1H-1,2,3-triazol-1-yl) -2- Amide (3f);
(7) Synthesis of methyl 4- (1- (4-hydroxy-3 - ((3- (trifluoromethyl) phenylcarbamoyl) phenyl-1H-1,2,3-triazol- Eat (3g);
(8) Synthesis of 2-hydroxy-5- (4- (m-tolyl) -1H-1,2,3-triazol-1-yl) -N- (3- (trifluoromethyl) (3h);
(9) Synthesis of 2-hydroxy-5- (4- (thiophen-3-yl) -1H-1,2,3-triazol- ) Benzamide (31);
(10) Synthesis of 5- (4- (3-acetamidophenyl) -1H-1,2,3-triazol-1-yl) -2- ) Benzamide (3m); And
(11) Methyl 3- (1- (4-hydroxy-3 - ((3- (trifluoromethyl) phenylcarbamoyl) Benzoate (3n). delete delete delete delete delete delete Cancer of the pancreas, breast, respiratory tract, brain, reproductive organs, digestive organs, urinary tract, eye, liver, skin, head and neck, thyroid or parathyroid, or the like, including the compound of claim 1 or a pharmaceutically acceptable salt thereof. A pharmaceutical composition for preventing or treating aurora kinase-related disease which is a distal potential of a solid tumor. delete delete 9. The composition of claim 8, wherein said composition is selected from the group consisting of a cell signaling inhibitor, a mitotic inhibitor, an alkylating agent, an anti-metabolite, an insertion antibiotic, a growth factor inhibitor, a cell cycle inhibitor, a topoisomerase inhibitor, a biologic response modifier, Wherein the pharmaceutical composition further comprises an anti-cancer agent selected from the group consisting of anti-angiogenic agents, anti-angiogenic agents, anti-angiogenic agents, anti-angiogenic agents, anti-angiogenic agents,